ArticleClinical cancer research : an official journal of the American Association for Cancer Research2021
Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP).ESMO open · 2025Trial
- Real-World Outcomes of Olaparib in Japanese Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer: Exploratory Analysis of BRCA2 Loss and Microsatellite Instability Status.International journal of urology : official journal of the Japanese Urological Association · 2026Article
- Article
- Olaparib for patients with tumors harboring alterations in homologous recombination repair genes: Results from the drug rediscovery protocol.International journal of cancer · 2026Article
- Molecular reflex testing in patients with early metastatic castration-resistant prostate cancer within the PROMPT-study.British journal of cancer · 2026Observational
- Synthetic lethal strategies for the development of cancer therapeutics.Nature reviews. Clinical oncology · 2025Review
- Genomic instability in non-breast or ovarian malignancies of individuals with germline pathogenic variants in BRCA1/2.Journal of the National Cancer Institute · 2024Article
- Familial Pancreatic Cancer Research: Bridging Gaps in Basic Research and Clinical Application.Biomolecules · 2024Review
- Deleterious alterations in homologous recombination repair genes and efficacy of platinum-based chemotherapy in biliary tract cancers.The oncologist · 2024Article
- Clinical actionability of BRCA2 alterations in uterine leiomyosarcoma: a molecular tumor board case report and a cBioPortal comprehensive analysis.The oncologist · 2024Article
- The evolution of precision oncology: The ongoing impact of the Drug Rediscovery Protocol (DRUP).Acta oncologica (Stockholm, Sweden) · 2024Article
- PCM4EU and PRIME-ROSE: Collaboration for implementation of precision cancer medicine in Europe.Acta oncologica (Stockholm, Sweden) · 2024Article
- A national precision cancer medicine implementation initiative for Finland.Acta oncologica (Stockholm, Sweden) · 2024Article
- Homologous Recombination Deficiency Landscape of Breast Cancers and Real-World Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Patients With SomaticJCO precision oncology · 2023Article
- Clinical Response to a PARP Inhibitor and Chemotherapy in a Child with BARD1-Mutated Refractory Neuroblastoma: A Case Report.Research square · 2023Article
- HRD Testing of Ovarian Cancer in Routine Practice: What Are We Dealing With?International journal of molecular sciences · 2023Article
- Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers.Nature communications · 2023Article
- Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours.BMC cancer · 2023Article
- Case Report: Progressive disease of BRCA2-mutant colon adenocarcinoma following talazoparib therapy.Frontiers in oncology · 2023Article
Corrections and comments
- Comment on
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo assess the efficacy of olaparib, a PARP inhibitor (PARPi) in patients with tumors with PATIENTS AND
methodsPatients with treatment-refractory
resultsTwenty-four evaluable patients with nine different tumor types harboring
conclusionsThese data indicate that using PARPis is a promising treatment strategy for patients with non-
Indexed as
Identifiers
34475104What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.